Immunocore Holdings plc (NASDAQ:IMCR) Receives $65.64 Consensus Price Target from Brokerages

Immunocore Holdings plc (NASDAQ:IMCR) has received a consensus recommendation of “Moderate Buy” from the thirteen ratings firms that are presently covering the stock, MarketBeat reports. One analyst has rated the stock with a sell rating, four have assigned a hold rating and eight have given a buy rating to the company. The average 12-month price target among brokerages that have covered the stock in the last year is $65.64.

Several research analysts have recently weighed in on IMCR shares. Mizuho cut shares of Immunocore from an “outperform” rating to a “neutral” rating and reduced their price target for the company from $72.00 to $38.00 in a report on Monday, November 11th. UBS Group started coverage on shares of Immunocore in a research note on Thursday, October 24th. They issued a “sell” rating and a $24.00 target price for the company. Guggenheim downgraded Immunocore from a “buy” rating to a “neutral” rating in a research note on Monday, October 7th. HC Wainwright reaffirmed a “buy” rating and set a $100.00 price objective on shares of Immunocore in a research report on Thursday, October 24th. Finally, Morgan Stanley reissued an “equal weight” rating and issued a $35.00 target price (down previously from $74.00) on shares of Immunocore in a research report on Friday, December 13th.

Institutional Investors Weigh In On Immunocore

Several institutional investors have recently made changes to their positions in IMCR. Exchange Traded Concepts LLC lifted its position in Immunocore by 40.4% during the third quarter. Exchange Traded Concepts LLC now owns 5,075 shares of the company’s stock worth $158,000 after purchasing an additional 1,461 shares during the period. Connective Portfolio Management LLC bought a new stake in shares of Immunocore during the 3rd quarter worth approximately $218,000. China Universal Asset Management Co. Ltd. boosted its position in shares of Immunocore by 69.7% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 7,433 shares of the company’s stock worth $231,000 after acquiring an additional 3,053 shares in the last quarter. XTX Topco Ltd bought a new position in Immunocore in the second quarter valued at approximately $303,000. Finally, GSA Capital Partners LLP bought a new position in Immunocore in the third quarter valued at approximately $406,000. 84.50% of the stock is currently owned by institutional investors.

Immunocore Price Performance

IMCR opened at $30.82 on Friday. The stock has a market cap of $1.54 billion, a P/E ratio of -32.44 and a beta of 0.76. Immunocore has a 12 month low of $27.69 and a 12 month high of $76.98. The company has a quick ratio of 3.76, a current ratio of 3.78 and a debt-to-equity ratio of 1.03. The company has a fifty day simple moving average of $31.23 and a 200 day simple moving average of $33.85.

Immunocore (NASDAQ:IMCR) last released its quarterly earnings results on Wednesday, November 6th. The company reported $0.17 EPS for the quarter, topping analysts’ consensus estimates of ($0.33) by $0.50. Immunocore had a negative return on equity of 12.84% and a negative net margin of 15.87%. The company had revenue of $80.25 million for the quarter, compared to analyst estimates of $78.94 million. During the same quarter last year, the firm posted ($0.59) earnings per share. Immunocore’s revenue was up 23.7% compared to the same quarter last year. On average, research analysts expect that Immunocore will post -0.94 EPS for the current year.

About Immunocore

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma.